<DOC>
	<DOCNO>NCT01010984</DOCNO>
	<brief_summary>The purpose study determine LC bead load Doxorubicin safe effective treatment melanoma spread liver .</brief_summary>
	<brief_title>LC Bead Embolization Agent With Doxorubicin Treatment Liver Metastasis From Melanoma</brief_title>
	<detailed_description>In study , trans-arterial chemoembolization use deliver LC bead load Doxorubicin directly liver tumor result malignant melanoma .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Patients unresectable , measurable disease define least one lesion accurately serially measure per modify RECIST EASL criterion ( 2D/3DEASL ) MRI ( Extent Necrosis ) Patients ≥ 18 year age , &gt; 35kg , race sex , histological radiological proof melanoma liver ECOG performance status &lt; 3 Patient chooses participate sign informed consent document Patients unilobar disease treat superselectively single session patient bilobar disease lobes able treat within 3 4 week separate session Patients patent main portal vein Ocular melanoma allow Patients clinically radiologically stable brain metastasis melanoma include Patients liver dominant disease ( &gt; 50 % overall tumor burden ) Prior systemic therapy metastatic disease allow Nonpregnant acceptable contraception premenopausal woman fertile men Hematological function : ANC ≥1.5 x 109/L , platelet ≥ 75 x 109/L , INR ≤1.3 ( patient therapeutic anticoagulant eligible ) Adequate renal function : Creatinine ≤2.0mg/dl GFR &gt; 30 Adequate liver function : total bilirubin ≤ 2.5 mg/dl , ALT , AST ≤ 5 time ULN , albumin ≥ 2.5mg/dl All toxic effect prior therapy must resolve ≤ Grade 1 unless otherwise specify Women pregnant breast feeding Patients eligible curative treatment resection radiofrequency ablation Active bacterial , viral fungal infection within 72 hour study entry Previous concurrent cancer distinct primary site histology cancer evaluate study except cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor ( TA , Tis &amp; Ti ) cancer curatively treat &lt; 5 year prior study entry Contraindication hepatic artery embolization procedure : Severe peripheral vascular disease preclude catheterization Large shunt determine investigator ( pretesting TcMAA require ) time first angiogram Hepatofugal blood flow Main portal vein occlusion ( e.g . thrombus tumor ) Recovery major trauma include surgery within 4 week prior administration study treatment . Allergy contrast medium manage standard care ( e.g . steroid ) , make magnetic resonance imaging ( MRI ) compute tomography ( CT ) contraindicate Advanced liver disease ( &gt; 80 % liver replacement ) Other significant medical surgical condition , medication treatment would place patient undue risk would preclude safe use chemoembolization would interfere study participation Any contraindication doxorubicin administration : WBC &lt; 3000 cells/mm3 Neutrophils &lt; 1500 cells/mm3 Deficient cardiac function define LVEF &lt; 50 % normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>metastatic melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>metastatic melanoma liver</keyword>
</DOC>